特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

クローン病 (限局性回腸炎) :世界の治験動向

Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019

発行 GlobalData 商品コード 232266
出版日 ページ情報 英文 901 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
クローン病 (限局性回腸炎) :世界の治験動向 Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019
出版日: 2019年12月04日 ページ情報: 英文 901 Pages
概要

当レポートでは、クローン病 (限局性回腸炎) に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域 主要国における治験件数; 中南米

G7諸国における治験件数:クローン病 (限局性回腸炎) 治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:クローン病 (限局性回腸炎) 治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - クローン病 (限局性回腸炎) 治療薬

有望な薬剤

最新治験ニュース:クローン病 (限局性回腸炎)

治験プロファイルの基本情報

付録

図表

図表

List of Tables

  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region, 2019* 8
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
  • Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 18
  • Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
  • Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 23
  • Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 26
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase, 2019* 27
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 30
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
  • Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 35
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures

  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
  • Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 17
  • Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
  • Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 22
  • Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28
  • Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
  • Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36
  • Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38
  • GlobalData Methodology 900
目次
Product Code: GDHC5163CTIDB

GlobalData's clinical trial report, "Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019" provides an overview of Crohn's Disease (Regional Enteritis) clinical trials scenario. This report provides top line data relating to the clinical trials on Crohn's Disease (Regional Enteritis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 28
  • Clinical Trials by Trial Status 29
  • Clinical Trials by End Point Status 31
  • Subjects Recruited Over a Period of Time 32
  • Clinical Trials by Sponsor Type 33
  • Prominent Sponsors 34
  • Top Companies Participating in Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials 36
  • Prominent Drugs 38
  • Latest Clinical Trials News on Crohn's Disease (Regional Enteritis) 39
  • Nov 22, 2019: Abivax to expand Phase IIb ulcerative colitis trial to France 39
  • Nov 06, 2019: Protagonist Therapeutics announces first patient dosed in a phase 2 study of oral IL-23 receptor antagonist PTG-200 (JNJ-67864238) in the treatment of Crohn's Disease 39
  • Oct 28, 2019: Formycon announces start of phase I clinical trial with Ustekinumab Biosimilar candidate FYB202 39
  • Oct 28, 2019: RedHill Biopharma to Present New Phase 3 Data on RHB-104 at the American College of Gastroenterology 2019 Annual Meeting 40
  • Oct 23, 2019: Provention Bio reports mixed results from Crohn's disease study 40
  • Oct 21, 2019: Retrospective real-world comparative analysis highlights safety of vedolizumab and Anti-TNFa therapies in biologic-naive patients with Ulcerative Colitis or Crohn's Disease 40
  • Oct 21, 2019: Biogen and Samsung Bioepis to present data for Adalimumab biosimilar at United European Gastroenterology Week 41
  • Oct 17, 2019: NeuClone announces first human dose of Stelara (Ustekinumab) Biosimilar candidate in phase I clinical trial 42
  • Oct 11, 2019: RedHill Biopharma announces full results from positive MAP US phase 3 study and supportive top-line results from MAP US2 open-label extension study with RHB-104 in Crohn's Disease 42
  • Sep 27, 2019: Takeda reports further results from VARSITY ulcerative colitis study 43
  • Clinical Trial Profile Snapshots 44

Appendix 938

  • Abbreviations 938
  • Definitions 938
  • Research Methodology 939
  • Secondary Research 939
  • About GlobalData 940
  • Contact Us 940
  • Source 941